In as much as they don't have that many launches coming through at the moment, they can afford to ease up a bit on the marketing spend.

The gross margin expansion is really coming through from switch from urinary to recombinant products. It bodes well for 2001.

If the U.S. order is as big as rumored, the sales will be recorded over 2005/2006, and possibly into 2007 depending on how much product Roche can deliver.

It's a major part of our business, very important.

We've had a light day today.

That was the one major factor that, when they discontinued its use, the numbers recovered.